Corrigendum to “KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 study” [Leuk. Res. 50 (Nov) (2016) 123–131. PubMed PMID: 27736729]

Saved in:
Bibliographic Details
Published inLeukemia research Vol. 59; p. 65
Main Authors Swords, Ronan T., Greenberg, Peter L., Wei, Andrew H., Durrant, Simon, Advani, Anjali S., Hertzberg, Mark S., Lewis, Ian D., Rivera, Gabriel, Gratzinger, Dita, Fan, Alice C., Felsher, Dean W., Cortes, Jorge E., Watts, Justin M., Yarranton, Geoff T., Walling, Jackie M., Lancet, Jeffrey E.
Format Journal Article
LanguageEnglish
Published England Elsevier Ltd 01.08.2017
Subjects
Hematology, Oncology and Palliative Medicine
Online AccessGet full text

Cover

More Information
Bibliography:erratum
ISSN:0145-2126
1873-5835
DOI:10.1016/j.leukres.2017.02.007